These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12506864)

  • 21. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactic acidosis in HIV patients receiving highly active antiretroviral therapy.
    Chow YW; Leong CL; Chow HL; Hooi LS
    Med J Malaysia; 2007 Mar; 62(1):78-80. PubMed ID: 17682581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lactic acidosis in Africans receiving HAART.
    Kemper CA
    AIDS Alert; 2007 Sep; 22(9):106-8. PubMed ID: 18411465
    [No Abstract]   [Full Text] [Related]  

  • 24. Severe dyshidrosis in two patients with HIV infection shortly after starting highly active antiretroviral treatment.
    Colebunders R; Zolfo M; Lynen L
    Dermatol Online J; 2005 Aug; 11(2):31. PubMed ID: 16150239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein CIII and highly active antiretroviral therapy (HAART)-induced hypertriglyceridemia.
    Badiou S; Dupuy AM; Baillat V; Fabre J; Tur MD; Cristol JP; Reynes J
    Clin Lab; 2003; 49(1-2):11-3. PubMed ID: 12593470
    [No Abstract]   [Full Text] [Related]  

  • 26. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Fernández Cotarelo MJ; Abellán Martínez J; Guerra Vales JM; Martínez Sánchez P; Rodrigo Gómez De La Bárcena M; Salto Fernández E
    Clin Infect Dis; 2003 Oct; 37(7):973-7. PubMed ID: 13130410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic toxicities and HIV.
    McGuire S
    Posit Aware; 2002; 13(6):23-5. PubMed ID: 12484331
    [No Abstract]   [Full Text] [Related]  

  • 29. Progressive neuropsychiatric problems following institution of highly active antiretroviral therapy.
    Miller RF; Dave SS; Tang JW; Shaw PJ; Jäger HR; Wilkins EG
    Sex Transm Infect; 2005 Aug; 81(4):351-7. PubMed ID: 16061546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy.
    Matsukura M; Chu FF; Au M; Lu H; Chen J; Rietkerk S; Barrios R; Farley JD; Montaner JS; Montessori VC; Walker DC; Côté HC
    AIDS; 2008 Jun; 22(10):1226-9. PubMed ID: 18525271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HAART-associated lymphadenopathy.
    Ball SC; Chadburn A
    AIDS Read; 1999; 9(1):11-2, 17. PubMed ID: 12728876
    [No Abstract]   [Full Text] [Related]  

  • 33. What happens to children growing up with HIV infection? It's time for a HAART to heart.
    Viganò A; Pattarino G; Cerini C; Zuccotti GV
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):495-8. PubMed ID: 19485788
    [No Abstract]   [Full Text] [Related]  

  • 34. Nutrition. Study finds vitamin B12 levels low in some HAART users.
    TreatmentUpdate; 2003 Oct; 15(6):6-7. PubMed ID: 17216864
    [No Abstract]   [Full Text] [Related]  

  • 35. Mortality after myocardial infarction in HIV-infected patients who have initiated HAART.
    Rasmussen LD; Gerstoft J; Kronborg G; Larsen CS; Pedersen G; Obel N
    AIDS; 2007 Apr; 21(7):873-5. PubMed ID: 17415045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.
    Butt AA; Fultz SL; Kwoh CK; Kelley D; Skanderson M; Justice AC
    Hepatology; 2004 Jul; 40(1):115-9. PubMed ID: 15239093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HAART to heart talk.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):8-9. PubMed ID: 12751445
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-HIV agents. Should HAART begin right after an HIV diagnosis?
    TreatmentUpdate; 2009; 21(3):2-3. PubMed ID: 19630120
    [No Abstract]   [Full Text] [Related]  

  • 39. Highly active antiretroviral therapy and viral response in HIV type 2 infection.
    Mullins C; Eisen G; Popper S; Dieng Sarr A; Sankale JL; Berger JJ; Wright SB; Chang HR; Coste G; Cooley TP; Rice P; Skolnik PR; Sullivan M; Kanki PJ
    Clin Infect Dis; 2004 Jun; 38(12):1771-9. PubMed ID: 15227626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side effects and complications. HAART and the safety of the fetus.
    TreatmentUpdate; 2009 Feb; 21(2):6-7. PubMed ID: 19391263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.